# Morphine Market

> Morphine Market Research Report Information By Dosage Form (Injection, Oral, and Other Dosage Forms), By Application (Pain Management, Diarrhea Suppressant, Cold & Cough Suppressant, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 7.2%
- **2025:** USD 30.7 Billion
- **2035:** USD 61.5 Billion
- **Key Players:** Pfizer Inc. (Hospira), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Mallinckrodt Pharmaceuticals, Purdue Pharma L.P., Rhodes Pharmaceuticals L.P., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.

**Report ID:** MRFR/HC/9162-HCR · **Pages:** 120 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** October 12, 2026

**URL:** https://www.marketresearchfuture.com/reports/morphine-market-10643

---

## Market Summary

As per Market Research Future analysis, the Morphine Market Size was estimated at 17.27 USD Billion in 2024. The Morphine industry is projected to grow from 18.39 USD Billion in 2025 to 34.53 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.5% during the forecast period 2025 - 2035

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising cancer incidence and palliative care need | +1.4% | Global | Long-term (≥4 yr) | [1][2] |
| Growing global surgical volumes | +1.1% | Global, strongest in Asia-Pacific | Medium-term (2–4 yr) | [3] |
| Essential-medicine access reforms | +0.9% | Asia-Pacific, Africa | Long-term (≥4 yr) | [5][17] |
| Smart infusion and IV safety upgrades | +0.8% | North America, Europe | Short-term (≤2 yr) | [7] |
| Abuse-deterrent formulation innovation | +0.7% | North America | Medium-term (2–4 yr) |  |
| Population aging and hospice expansion | +0.6% | Europe, Japan, North America | Long-term (≥4 yr) | [18] |

### Rising Cancer Incidence and Palliative Care Need

IARC estimates 20 million new cancer cases and 9.7 million cancer deaths in 2022, with annual cases projected to exceed 35 million by 2050 [1]. Moderate-to-severe pain affects a large share of advanced-stage patients, and morphine remains the first-line strong opioid in WHO pain guidance. WHO also estimates that only about 14% of people needing palliative care currently receive it [2], which leaves substantial untreated demand that health systems are slowly converting into prescriptions.

### Growing Global Surgical Volumes

The Lancet Commission on Global Surgery counted roughly 313 million procedures performed annually and found that 5 billion people lack access to safe, affordable surgery [3]. Each expansion of operating capacity in middle-income countries adds perioperative analgesia demand, where intravenous morphine remains a low-cost standard. Hospital construction programs in India, Southeast Asia, and the Gulf states translate this gap into multi-year injectable procurement contracts.

### Essential-Medicine Access Reforms

India's NDPS (Amendment) Act 2014 created an "essential narcotic drugs" category that replaced multiple state licenses with a single authority, simplifying morphine stocking for hospitals and hospices [17]. The 2023 WHO Model List of Essential Medicines again retained oral and injectable morphine [5], giving ministries a clear reference when drafting national formularies. These reforms convert policy intent into recurring public tenders.

### Smart Infusion and IV Safety Upgrades

Observational research found at least one error in 60% of intravenous administrations across ten hospitals using smart pumps [7]. That evidence has pushed health systems to fund pump-EHR interoperability, standardized drug libraries, and prefilled syringes. Morphine, as a high-alert medication, sits near the top of these protocols, and upgraded workflows raise the per-dose value hospitals assign to compatible, standardized injectable presentations.

### Abuse-Deterrent Formulation Innovation

FDA's guidance on evaluating and labeling abuse-deterrent opioids set a four-category testing framework that still governs extended-release development . In April 2023, FDA also required updated labeling for immediate-release and extended-release opioids, sharpening differentiation by risk profile . Manufacturers that can document lower manipulation potential earn formulary placement and premium pricing, keeping research spend directed at morphine delivery technologies.

### Population Aging and Hospice Expansion

WHO projects that one in six people worldwide will be aged 60 or over by 2030 [18]. Older patients carry higher rates of cancer, chronic pain, and end-of-life care needs, which raises hospice enrollment in Europe, Japan, and North America. Home-based palliative programs favor oral and subcutaneous morphine regimens, widening the channel mix beyond acute hospital settings.

## Restraints

## Restraints Impact Analysis

Restraint impacts are directional estimates of downward pressure on the Morphine Market CAGR. They are not additive and partly offset the drivers in Section 4.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Opioid misuse controls and prescribing limits | -0.9% | North America, Europe | Medium-term (2–4 yr) | [10][11] |
| Litigation and settlement liabilities | -0.7% | United States | Medium-term (2–4 yr) | [14][15] |
| Injectable shortages and production quotas | -0.6% | North America | Short-term (≤2 yr) | [12][23] |
| Access barriers in low- and middle-income countries | -0.5% | Africa, South Asia, Latin America | Long-term (≥4 yr) | [4] |
| Substitution by non-opioid analgesics | -0.4% | North America, Europe | Long-term (≥4 yr) |  |

### Opioid Misuse Controls and Prescribing Limits

The CDC's 2022 Clinical Practice Guideline urges clinicians to maximize non-opioid therapy and to prescribe the lowest effective opioid dose for the shortest duration [10]. Provisional CDC data show U.S. overdose deaths fell about 27% in 2024 [11], but payers and state boards keep strict prior-authorization and quantity limits in place, capping outpatient volume growth.

### Litigation and Settlement Liabilities

National opioid settlements with makers, distributors and pharmacies total more than USD 50 billion. In June 2024, the U.S. Supreme Court ruled in Harrington v. Purdue Pharma to reject nonconsensual third-party releases [14], necessitating a renegotiated USD 7.4 billion Purdue settlement in 2025 [15]. Legal reserves detract resources from portfolio investing and make some corporations wary of advertising oral painkillers.

### Injectable Shortages and Production Quotas

In the first quarter of 2024, ASHP reported a record 323 active U.S. medicine shortages, with sterile injectables well represented [12]. DEA aggregate production regulations limit morphine manufacture annually [23], leaving little margin for error when a sterile-fill process goes down. Shortages compel clinicians to seek alternatives, and some substitutes continue when supply is restored.

### Access Barriers in Low- and Middle-Income Countries

The Lancet Commission on Palliative Care and Pain Relief found that low-income countries receive only a tiny fraction of the world's distributed morphine-equivalent opioids, despite carrying most serious health-related suffering [4]. Restrictive licensing, limited pharmacist training, and fear of diversion keep consumption far below clinical need, slowing volume conversion in the regions with the largest gaps.

### Substitution by Non-Opioid Analgesics

FDA approved suzetrigine in January 2025 as the first drug in a new non-opioid class for moderate-to-severe acute pain . Combined with enhanced recovery protocols using regional anesthesia and multimodal regimens, such options are trimming opioid use after many common procedures. The effect concentrates in outpatient surgery rather than oncology.

## Opportunities

## Morphine Market Opportunities

### Palliative Access Expansion in Emerging Markets

India's simplified licensing [17] and WHO's essential-medicine guidance [5] create room for low-cost oral and injectable supply into public tenders across South Asia and Sub-Saharan Africa. Suppliers that pair product with pharmacist training and stock-management support can win multi-year national contracts and help translate palliative morphine therapy from policy into routine care.

### Next-Generation Extended-Release Formulations

Revised FDA labeling rules  offer an incentive to products that clearly demonstrate abuse-deterrent qualities. Microsphere and polymer-matrix technologies provide a pathway to distinct extended-release medicines with justifiable pricing, especially for chronic cancer pain patients requiring sustained 12- or 24-hour coverage.

### Ready-to-Administer Hospital Presentations

Prefilled syringes and premixed infusion bags reduce compounding time and dosing errors [7], and hospitals increasingly specify them in group purchasing contracts. Suppliers with sterile-fill capacity in North America and Europe can capture share left open by recurring shortages [12].

### Telehealth-Enabled Dispensing and Data-Driven Models

The DEA’s extension of telemedicine prescribing flexibilities through 2025 [13] has kept remote controlled-substance prescribing possible for existing patients. Verified dispensing analytics, track and trace services, and adherence solutions supplied to payers and hospice operators can generate additional revenue for digital pharmacies and wholesalers.

### Targeted Delivery for Refractory Cancer Pain

Intrathecal pump programs serve patients whose systemic opioid dosing fails or causes intolerable side effects. Specialty pharmacies and device partners that offer preservative-free formulations and refill services can capture high-value niche revenue as oncology centers expand interventional pain teams.

## Future Outlook

## Morphine Market Future Outlook

### Demographic and Oncology Demand

IARC projects cancer cases rising past 35 million annually by 2050 [1], and WHO expects the population aged 60 and over to reach 1.4 billion by 2030 [18]. Together, these trends make palliative and cancer pain the most durable demand base for the Morphine Market through 2035, largely insulated from outpatient prescribing restrictions.

### Digital Stewardship and Diversion Control

Prescription drug monitoring programs, automated dispensing cabinets, and analytics that flag unusual withdrawal patterns will become standard hospital infrastructure. Regulators increasingly view these tools as conditions for expanded access, so suppliers that integrate serialized packaging and dispensing data will hold an advantage in contracting.

### Supply Chain Resilience

Recurring sterile-injectable shortages [12] and quota-limited production [23] will push governments and group purchasing organizations to reward domestic and dual-sourced manufacturing. Expect more long-term supply agreements with minimum-volume guarantees and investment in regional fill-finish capacity in North America, Europe, and India.

### Rebalancing Access and Control

The INCB continues to document a wide gap between morphine consumption in high-income and low-income countries [6]. Policy direction over the decade points toward tighter outpatient controls in mature markets alongside liberalized medical access in emerging ones, shifting the regional revenue mix steadily toward Asia-Pacific and the Middle East.

## Segment Insights

## Morphine Market Segmentation

### By Dosage Form

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Injection | 41.9% share | Rapid onset and titratable dosing in acute care |

Within the Morphine Market, Injection is the anchor dosage form, holding a 41.9% share in 2025. Operating rooms, emergency departments, and intensive-care units depend on its rapid onset and precise titration. Shortages periodically push some patients to oral alternatives, yet sustained surgical growth keeps injectables firmly ahead in absolute revenue. Prefilled syringes and premixed bags are lifting value per dose as hospitals standardize high-alert medication workflows [7].

### By Release Type

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Immediate-Release (IR) | 55.8% share | Prescriber familiarity and breakthrough pain dosing |

Across the Morphine Market, Immediate-Release (IR) products command a 55.8% share, reflecting deep prescriber familiarity, simple reimbursement, and their role in breakthrough and acute pain. Extended-release and controlled-release morphine products complement IR therapy in chronic regimens, and FDA's 2023 labeling updates  are clarifying risk messaging for both. IR remains the dosing backbone for titration before patients transition to longer-acting therapy.

### By Route of Administration

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Intravenous | USD 16.4 Billion | Perioperative and critical-care analgesia |

Intravenous delivery generated USD 16.4 Billion of Morphine Market revenue in 2025, concentrated in perioperative care, patient-controlled analgesia, and critical care. Smart-pump drug libraries and EHR-linked dosing alerts are improving safety and justifying higher-value presentations. Intrathecal, intramuscular, and subcutaneous routes retain specialized niches, but intravenous protocols remain the default where fast, adjustable analgesia is clinically essential.

### By Application

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Pain Management | 65.4% share | Surgical, trauma, and chronic pain protocols |
| Cancer Pain | 7.9% CAGR | Rising cancer incidence and palliative access |

Pain Management dominates the Morphine Market with a 65.4% share, spanning postoperative, trauma, and chronic pain protocols. Cancer Pain is the fastest-growing component at a 7.9% CAGR, driven by rising incidence [1] and expanding palliative programs in Asia-Pacific and the Middle East. Oncology use is the least exposed to outpatient prescribing limits, giving this sub-segment the most predictable long-term demand profile.

### By End-User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | USD 11.0 Billion | Surgical volume and inpatient oncology |

Hospitals account for USD 11.0 Billion of Morphine Market demand, reflecting their control of injectable dispensing, controlled-substance storage, and perioperative care. Group purchasing contracts increasingly weight supply reliability over unit price after repeated shortages [12]. Retail and online pharmacies serve chronic and hospice patients, but hospitals remain the primary channel for high-volume, high-acuity use through 2035.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 39.5% share | Prefilled injectables, abuse-deterrent formulations, shortage resilience |
| Europe | USD 8.0 Billion | Hospice expansion, national palliative strategies |
| Asia-Pacific | 8.3% CAGR | Licensing reform, hospital construction, oncology centers |
| South America | 4.6% share | Public procurement, cancer-care networks |
| Middle East & Africa | USD 1.2 Billion | Tertiary hospital build-out, access programs |
| Total | USD 30.7 Billion | — |

Regional performance in the Morphine Market tracks two variables: surgical and oncology capacity in mature systems, and regulatory liberalization in emerging ones.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| US | 86.2% share of region | Surgical volume, hospice reimbursement |
| Canada | 7.0% CAGR | Provincial palliative care funding |
| Mexico | USD 0.6 Billion | Public hospital expansion |

The U.S. dominates the North American Morphine Market through high procedure volumes and Medicare hospice coverage, though CDC prescribing guidance [10] restrains outpatient growth. Hospital demand stays resilient, and shortage-driven contracting [12] favors suppliers with redundant sterile capacity. Canada's provincial palliative programs support steady growth, while Mexico's public health reforms aim to raise historically low per-capita opioid availability.

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 22.4% share of region | Large hospital base, aging population |
| UK | USD 1.5 Billion | NHS end-of-life care pathways |
| France | 6.6% CAGR | National palliative care plan |
| Italy | 11.8% share of region | Simplified opioid prescribing rules |
| Spain | USD 0.7 Billion | Regional hospice investment |
| Nordic Countries | 6.9% CAGR | Home-based palliative models |
| Russia | 7.5% share of region | Gradual easing of opioid access rules |
| Rest of Europe | USD 1.0 Billion | EU-funded oncology infrastructure |

Germany leads Europe through dense hospital infrastructure and one of the continent's oldest populations [18]. The UK relies on NHS end-of-life pathways that favor oral and subcutaneous regimens in community settings. Italy's earlier reforms simplifying opioid prescribing continue to lift utilization, and France's national palliative plan adds hospital-based teams. Eastern markets remain under-supplied relative to cancer burden, offering long-run upside.

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 8.7% CAGR | Oncology hospital expansion |
| India | 9.1% CAGR | NDPS licensing reform |
| Japan | 27.5% share of region | Super-aged population, cancer care |
| South Korea | USD 0.6 Billion | Hospice insurance coverage |
| ASEAN | 8.5% CAGR | Universal health coverage rollouts |
| Rest of Asia-Pacific | 9.8% share of region | Australian palliative programs |

Asia-Pacific is the growth engine of the Morphine Market. India's single-license system for essential narcotic drugs [17] has expanded the number of recognized medical institutions able to stock morphine, while China's oncology hospital build-out lifts injectable demand. Japan holds the largest regional share, driven by a super-aged population, although cautious prescribing culture keeps per-patient doses below Western levels. ASEAN universal-coverage programs add public tender volume.

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58.3% share of region | SUS cancer-care network |
| Argentina | USD 0.2 Billion | Public oncology programs |
| Rest of South America | 6.8% CAGR | Palliative care law adoption |

Brazil anchors the region through its unified public health system and a large oncology patient base. Argentina's public programs sustain demand despite currency volatility that complicates imported supply. Several Andean countries have adopted palliative care legislation, but implementation depends on pharmacist training and stocking incentives, so growth remains uneven and tied to government purchasing cycles.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 7.6% CAGR | Vision 2030 hospital investment |
| UAE | USD 0.2 Billion | Specialty oncology centers |
| South Africa | 24.1% share of region | Established private hospital sector |
| Egypt | 8.0% CAGR | Universal health insurance rollout |
| Rest of MEA | USD 0.3 Billion | Donor-supported access programs |

Saudi Arabia's Vision 2030 health spending funds new tertiary hospitals and cancer centers, raising perioperative and oncology demand. South Africa holds the largest share through its private hospital sector. Across Sub-Saharan Africa, access remains far below need [4]; low-cost oral morphine programs supported by NGOs and ministries offer the most scalable route to wider coverage.

## Competitive Benchmarking

## Competitive Benchmarking

The Morphine Market is moderately concentrated, with an estimated HHI of 900–1,100 and the top five suppliers holding roughly 40–50% of revenue. Large sterile-injectable manufacturers dominate hospital supply, while generic and branded oral suppliers compete on formulation, cost, and compliance infrastructure. DEA quotas, licensing requirements, and litigation exposure act as strong entry barriers, keeping the field relatively stable.

| Company | Est. Revenue Share Range | Key Offerings for Morphine Market | Strategic Positioning |
| --- | --- | --- | --- |
| Pfizer Inc. (Hospira) | ~10–14% | Morphine sulfate injection in Carpuject cartridges and vials | Scale leader in hospital sterile injectables |
| Fresenius Kabi AG | ~8–11% | Simplist prefilled morphine syringes, vials | Ready-to-administer hospital formats |
| Hikma Pharmaceuticals PLC | ~7–10% | Injectable and oral solution morphine | Broad U.S. generic injectables footprint |
| Mallinckrodt Pharmaceuticals | ~6–9% | Morphine API and generic extended-release tablets | Vertically integrated controlled-substance producer |
| Purdue Pharma L.P. | ~5–8% | MS Contin extended-release tablets | Branded extended-release heritage under restructuring |
| Rhodes Pharmaceuticals L.P. | ~4–7% | Generic extended-release morphine | Generic arm with API integration |
| Sun Pharmaceutical Industries Ltd. | ~4–6% | Generic opioid analgesics and API | Cost-competitive emerging-market supply |
| Teva Pharmaceutical Industries Ltd. | ~3–6% | Generic extended-release morphine tablets | Global generics scale |
| Viatris Inc. | ~3–5% | Generic modified-release opioid portfolio | Diversified generics distribution |
| Mundipharma International | ~3–5% | MST Continus and oral morphine outside the U.S. | Palliative-focused ex-U.S. presence |

## Recent News & Developments

## Recent News & Developments

- FDA (April 2023): Required updated labeling for immediate-release and extended-release opioid analgesics, sharpening risk communication that shapes formulary decisions for morphine products
- WHO (July 2023): Published the 23rd Model List of Essential Medicines, retaining oral and injectable morphine as reference strong opioids and supporting national formulary adoption [5]
- ASHP (April 2024): Reported a record 323 active U.S. drug shortages, highlighting supply fragility in sterile injectables including opioids [12]
- U.S. Supreme Court (June 2024): Ruled in Harrington v. Purdue Pharma that nonconsensual third-party releases are not permitted, reopening settlement negotiations [14]
- DEA (November 2024): Extended telemedicine flexibilities for prescribing controlled substances through December 31, 2025, sustaining remote access for established patients [13]
- Purdue Pharma and State Attorneys General (January 2025): Announced a revised USD 7.4 billion settlement framework involving the Sackler family [15]
- FDA (January 2025): Approved suzetrigine as a first-in-class non-opioid treatment for moderate-to-severe acute pain, adding competitive pressure in outpatient settings
- Mallinckrodt and Endo (March 2025): Announced a merger combining two major controlled-substance and generics manufacturers, consolidating U.S. opioid API and finished-dose capacity [16]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | The Morphine Market covers injectable and oral morphine formulations across release types and routes of administration, used in pain management and supplied through hospital and pharmacy channels. |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 30.7 Billion |
| Market Size in 2035 | USD 61.5 Billion |
| CAGR (2026–2035) | 7.2% |
| Fastest Growing Segments | Cancer Pain (7.9% CAGR); Asia-Pacific (8.3% CAGR); India (9.1% CAGR); China (8.7% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Pfizer Inc., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Mallinckrodt Pharmaceuticals, Purdue Pharma L.P., Rhodes Pharmaceuticals L.P., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Mundipharma International |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: How do controlled-substance schedules affect Morphine Market entry for new suppliers?**
A: Morphine is a Schedule II substance in the U.S., so manufacturers need DEA registration and an annual quota allocation before commercial supply [23]. Quota timing, not demand, often sets how quickly a new entrant can scale.

**Q: What should hospital procurement teams prioritize when sourcing morphine injectables?**
A: Supplier redundancy matters more than unit price, because single-source contracts leave pharmacies exposed when a plant goes offline [12]. Dual-award agreements and prefilled formats with longer shelf life reduce emergency substitution risk.

**Q: Which Morphine Market participants carry the most litigation risk?**
A: Branded oral opioid makers and national distributors carry the heaviest exposure, given settlements tied to historical marketing and distribution practices [14][15]. Hospital-focused injectable suppliers face comparatively limited legal liability.

**Q: How do new non-opioid analgesics change the competitive outlook?**
A: Agents such as suzetrigine target moderate-to-severe acute pain where short opioid courses were standard [24]. They narrow outpatient demand but leave severe cancer and perioperative pain largely to morphine.

**Q: Is raw-material concentration a risk for the Morphine Market?**
A: Yes. Morphine API depends on licit opium poppy cultivation concentrated in a few countries under INCB oversight [6]. Weather or policy shocks in these sources can tighten raw-material availability within a single season.

**Q: How are hospitals using technology to reduce internal diversion?**
A: Automated dispensing cabinets, barcode scanning, and waste-reconciliation software link every dose to a user and patient record. Analytics flag outlier withdrawal patterns for pharmacy review, shortening detection time.

**Q: What regulatory detail matters most for exporters to emerging markets?**
A: Each shipment needs matching import and export authorizations within the destination country's INCB-confirmed annual estimate [6]. Countries that underestimate needs cannot receive extra volume until they file a supplementary estimate.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/morphine-market-10643*